词条 | Ranirestat |
释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 449870766 | ImageFile =Ranirestat.svg | ImageSize = | IUPACName = (3R)-2'-(4-bromo-2-fluorobenzyl)-1'H,2H,5H-spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5(2'H)-tetrone | OtherNames = | Section1 = {{Chembox Identifiers | UNII_Ref = {{fdacite|correct|FDA}} | UNII = Z26P56GFTV | CASNo_Ref = {{cascite|correct|??}} | CASNo=147254-64-6 | PubChem=153948 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 135685 | SMILES = c1cc2n(c1)[C@@]3(CC(=O)NC3=O)C(=O)N(C2=O)Cc4ccc(cc4F)Br | InChI = 1/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1 | InChIKey = QCVNMNYRNIMDKV-QGZVFWFLBS | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1 | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = QCVNMNYRNIMDKV-QGZVFWFLSA-N |Section2 = {{Chembox Properties | C=17 | H=11 | Br=1 | F=1 | N=3 | O=4 | MolarMass = 420.189 g/mol | Appearance = | Density = | MeltingPt = | BoilingPt = | Solubility = |Section3 = {{Chembox Hazards | MainHazards = | FlashPt = | AutoignitionPt = }} Ranirestat (also known as AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy by Dainippon Sumitomo Pharma and PharmaKyorin. It has been granted orphan drug status. The drug is to be used orally. TrialsA Canadian Phase III clinical trial has been completed. Phase III trials in Europe and the US started in June 2009 and are expected to complete in April 2013. Mechanism of actionRanirestat is aldose reductase inhibitor that acts by reducing sorbitol accumulation in cells. Aldose reductase is an enzyme that catalyzes one of the steps in sorbitol (polyol) pathway which is responsible for formation of fructose from glucose. Aldose reductase activity is increased, parallel to glucose blood levels, in tissues that are not insulin sensitive, including lenses, peripheral nerves and renal glomeruli. Sorbitol does not diffuse through cell membranes easily and therefore accumulates in these tissues, causing osmotic damage, leading to retinopathy and neuropathy. EfficacyResults from a Canadian double-blind, placebo-controlled biopsy Phase III clinical trial, involving total of 549 patients with diabetic sensorimotor polyneuropathy (DSP) randomly assigned to treatment with placebo or 10, 20, or 40 mg/day ranirestat for 52 weeks, showed that ranirestat appears to have effect on motor nerve function in mild to moderate DSP, but failed to show statistically significant difference in sensory nerve function. Efficacy of ranirestat was evaluated by nerve conduction studies, the modified Toronto Clinical Neuropathy Score (mTCNS), and quantitative sensory tests (QSTs).[1] See also
References{{Refimprove|date=September 2011}}1. ^{{Cite journal | last1 = Bril | first1 = V. | last2 = Hirose | first2 = T. | last3 = Tomioka | first3 = S. | last4 = Buchanan | first4 = R. | last5 = Ranirestat Study | first5 = G. | doi = 10.2337/dc08-2110 | title = Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy | journal = Diabetes Care | volume = 32 | issue = 7 | pages = 1256–1260 | year = 2009 | pmid = 19366965 | pmc =2699746 }} {{oral hypoglycemics}}{{gastrointestinal-drug-stub}} 3 : Aldose reductase inhibitors|Orphan drugs|Pyrrolopyrazines |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。